Real-world histotripsy shows low toxicity but uncertain benefit in advanced liver cancer

A real-world review of 972 patients who underwent histotripsy for liver tumors found low rates of laboratory toxicity and procedural complications, but an 11% mortality rate within 30 days that could not be attributed to the procedure. Researchers from the University of Virginia Health System said the contrast suggests that the treatment’s safety should not be confused with proof of meaningful benefit, particularly for patients whose cancers are advanced or whose life expectancy may be short.

The study, published in JAMA Network Open, examined outcomes among patients treated between 2023 and 2026. The analysis considered survival, liver function before and after treatment, and the risk of kidney injury. Early clinical studies supporting the Food and Drug Administration’s 2023 clearance of the procedure had reported encouraging technical effectiveness and safety in carefully selected patients, but the new review was designed to assess how histotripsy performed in broader clinical practice.

Histotripsy is a noninvasive treatment that uses focused sound waves to create air bubbles within diseased liver tissue. The bubbles destroy cancer cells, and the procedure is typically performed on an outpatient basis without a hospital stay. The approach is intended to treat liver tumors directly, without the incision required by surgery. The new findings indicate that the procedure itself was generally well tolerated: laboratory toxicity and procedural complications occurred at low rates, while liver function and kidney-injury outcomes were assessed as markers of treatment-related safety.

However, nearly 70% of the treatments in the analysis were performed in patients with metastatic cancer involving the liver, including some patients with pancreatic cancer. The researchers said this distribution raises questions about which patients with metastatic disease are most likely to benefit from a therapy directed specifically at liver tumors. They also emphasized that advanced cancer and overall disease burden may have contributed to the observed mortality, although the study cannot establish whether histotripsy caused any of the deaths. “That does not mean histotripsy caused those deaths,” said Allan Tsung, a surgical oncologist and chair of UVA Health’s Department of Surgery. “What it does tell us is that we need to better understand which patients are most likely to live long enough and have the right type of cancer to meaningfully benefit from this treatment.”

The authors said the timing of histotripsy therefore deserves careful consideration, especially for people with advanced disease and limited life expectancy. A procedure can be technically safe and still provide limited benefit if a patient’s cancer is too advanced for a liver-directed treatment to alter the broader course of illness. Tsung described the study’s broader implication in practical terms: the next question is not simply whether histotripsy can be performed, but when it should be performed and for whom. The analysis was observational and did not determine that the procedure caused the deaths or establish that histotripsy improved survival. Instead, it provides a real-world safety snapshot and identifies patient selection and treatment timing as priorities for future evaluation. The research team included Olivia Sears, Elio R. Bitar, Kaelyn C. Cummins, Natalie Blatz, Maclean Cook, Daniel Sheeran and Tsung; the report noted that Sheeran had served on HistoSonics’ Prior Medical Advisory Board.

Subject of Research: Real-world safety and patient-selection outcomes of noninvasive histotripsy for liver tumors

Article Title: Review reveals real-world results of new, incisionless liver cancer treatment

Article References: Review reveals real-world results of new, incisionless liver cancer treatment. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: histotripsy, liver cancer, focused ultrasound, real-world evidence, metastatic disease, patient selection, treatment safety, clinical outcomes, Review, reveals, real-world, results